The U.S. Food and Drug Administration announced Thursday that it has approved updated COVID‑19 vaccines from three manufacturers—Moderna, Novavax‑Sanofi and Pfizer‑BioNTech—for the 2026‑27 immunization season. The decision follows a recommendation from an FDA advisory committee that the new formulations should target the XFG variant, which has become the dominant strain circulating in the United States.
Vaccine lineup and technology
Four COVID‑19 shots are currently authorized for use in the United States. Moderna’s offerings include the mNEXSPIKE and Spikevax mRNA vaccines. Pfizer‑BioNTech’s product, marketed as Comirnaty, is also an mRNA‑based vaccine. Novavax‑Sanofi’s contribution is a protein‑based vaccine, which typically requires a longer manufacturing timeline but offers an alternative platform for those who prefer non‑mRNA options.
Timeline and production readiness
All three manufacturers had previously indicated they could produce the updated shots in time for the 2026‑27 vaccination campaign. The FDA’s approval clears the way for distribution to health providers and pharmacies nationwide as the new season approaches.
Advisory panel vote
In May, eight of the nine experts on the FDA’s advisory committee voted in favor of targeting the XFG variant for the upcoming season. The panel’s guidance was a key factor in the agency’s decision to move forward with the updated formulations.
Previous season’s target
For the 2025‑26 season, the FDA had recommended that vaccines focus on the LP.8.1 subvariant of the JN.1 strain. The shift to XFG reflects the virus’s ongoing evolution and the need for vaccine manufacturers to stay ahead of emerging variants.
Surveillance challenges
The Centers for Disease Control and Prevention’s COVID‑19 dashboard currently shows limited data on new strains, citing low sequencing submissions across the country. Public health officials continue to encourage laboratories and health systems to increase genomic surveillance to better track variant trends.
What this means for Americans
With the updated vaccines approved, health providers can begin ordering and administering the new shots as soon as they become available. The FDA’s action underscores the continued commitment of federal health agencies to protect the public’s health by ensuring vaccine formulations keep pace with the virus’s mutations.
Looking ahead
Stakeholders, including schools, employers and community health centers, are preparing for the upcoming vaccination season. The approval also signals to the broader medical community that the regulatory pathway for updating COVID‑19 vaccines remains robust, allowing for rapid response to future variants.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
